Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...

Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in patients with DNA mismatch repair-deficient (dMMR) early-stage solid cancers who ...

Researchers have identified two natural compounds, patulin and xestoquinol, as new inhibitors of the enzyme topoisomerase 1, ...

Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

In in vitro and in vivo preclinical studies, ficerafusp alfa + a KRAS-G12C inhibitor (G12Ci) was shown to be more effective than G12Ci alone, with G12Ci-resistant lung cancer cells remaining ...

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other ...

IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...